Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Corcept’s Phase III Corlux Study Shows Promise | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Corcept’s Phase III Corlux Study Shows Promise

Corcept Therapeutics Inc. achieved positive results from its Phase III study of Corlux for the treatment of Cushing's Syndrome.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Corcept Therapeutics Inc. achieved positive results from its Phase III study of Corlux for the treatment of Cushing’s Syndrome. The study evaluated the response of two treatment groups: one in patients who were glucose intolerant and one in patients who were hypertensive. Statistically significant improvement in the primary endpoint was achieved in both groups, with 60% responding in the glucose intolerant group and 43% in the hypertensive group. Also, safety data indicates that Corlux was well tolerated by Cushing’s Syndrome patients.

“The results of the study demonstrate that Corlux has the potential to become an important treatment option for patients suffering from Cushing’s Syndrome,” said Joseph Belanoff, M.D., chief executive officer of Corcept. “We remain on track to submit a NDA to the FDA for Corlux in Cushing’s Syndrome by the end of the first quarter of 2011 and continue to work toward our goal of making Corlux available to patients with this severe disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters